Sebastian Kapps, Jakob Mühlbacher, Dorian Kulifaj, Sophie Courjal, Farsad Eskandary, Martin Schiemann, Bernd Jilma, Georg A. Böhmig, Gregor Bond, Markus Wahrmann
{"title":"通过补体激活的经典途径控制Torque Teno病毒--使用Sutimlimab的首次人体试验的回顾性分析。","authors":"Sebastian Kapps, Jakob Mühlbacher, Dorian Kulifaj, Sophie Courjal, Farsad Eskandary, Martin Schiemann, Bernd Jilma, Georg A. Böhmig, Gregor Bond, Markus Wahrmann","doi":"10.1002/jmv.70039","DOIUrl":null,"url":null,"abstract":"<p>Torque Teno virus (TTV) load is linked with the functionality of its host's immune system and has been proposed as a potential monitoring tool for immune-modulating therapy. However, the immunological mechanisms of TTV control are incompletely understood. To assess the effect of the classical complement pathway on TTV, 64 healthy volunteers and 10 kidney transplant recipients treated with the anti-C1s antibody sutimlimab were analyzed for serum TTV copy numbers (c/mL) by qPCR. Overall, a correlation was observed between the decrease in complement activity caused by sutimlimab and the TTV load increase (<i>ρ</i> = −0.367, <i>p</i> < 0.001). Subgroup analysis indicated a trend toward TTV load increase in healthy volunteers following the highest sutimlimab dose compared to baseline (100 mg/kg body weight; median 3.5 log<sub>10</sub> c/mL, interquartile range [IQR] 2.8–4.4 vs. 2.9 log<sub>10</sub> c/mL, 0.8–3.5; <i>p</i> = 0.063). Administering multiple lower doses (30 mg/kg) also showed a trend toward TTV load increase in healthy volunteers (1.8 log<sub>10</sub> c/mL, 0–2.3 vs. 1.9, 1.3–2.8; <i>p</i> = 0.054) and a significant increase in transplant recipients (3.5 log<sub>10</sub> c/mL, 3.0–6.1 vs. 4.1, 3.5–6.4; <i>p</i> = 0.004). This report suggests a role for the classical complement pathway in controlling TTV load.</p>","PeriodicalId":16354,"journal":{"name":"Journal of Medical Virology","volume":null,"pages":null},"PeriodicalIF":6.8000,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jmv.70039","citationCount":"0","resultStr":"{\"title\":\"Torque Teno Virus Control by the Classical Pathway of Complement Activation—A Retrospective Analysis From a First-in-Human Trial Utilizing Sutimlimab\",\"authors\":\"Sebastian Kapps, Jakob Mühlbacher, Dorian Kulifaj, Sophie Courjal, Farsad Eskandary, Martin Schiemann, Bernd Jilma, Georg A. Böhmig, Gregor Bond, Markus Wahrmann\",\"doi\":\"10.1002/jmv.70039\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Torque Teno virus (TTV) load is linked with the functionality of its host's immune system and has been proposed as a potential monitoring tool for immune-modulating therapy. However, the immunological mechanisms of TTV control are incompletely understood. To assess the effect of the classical complement pathway on TTV, 64 healthy volunteers and 10 kidney transplant recipients treated with the anti-C1s antibody sutimlimab were analyzed for serum TTV copy numbers (c/mL) by qPCR. Overall, a correlation was observed between the decrease in complement activity caused by sutimlimab and the TTV load increase (<i>ρ</i> = −0.367, <i>p</i> < 0.001). Subgroup analysis indicated a trend toward TTV load increase in healthy volunteers following the highest sutimlimab dose compared to baseline (100 mg/kg body weight; median 3.5 log<sub>10</sub> c/mL, interquartile range [IQR] 2.8–4.4 vs. 2.9 log<sub>10</sub> c/mL, 0.8–3.5; <i>p</i> = 0.063). Administering multiple lower doses (30 mg/kg) also showed a trend toward TTV load increase in healthy volunteers (1.8 log<sub>10</sub> c/mL, 0–2.3 vs. 1.9, 1.3–2.8; <i>p</i> = 0.054) and a significant increase in transplant recipients (3.5 log<sub>10</sub> c/mL, 3.0–6.1 vs. 4.1, 3.5–6.4; <i>p</i> = 0.004). This report suggests a role for the classical complement pathway in controlling TTV load.</p>\",\"PeriodicalId\":16354,\"journal\":{\"name\":\"Journal of Medical Virology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":6.8000,\"publicationDate\":\"2024-11-06\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jmv.70039\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Medical Virology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/jmv.70039\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"VIROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Medical Virology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/jmv.70039","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"VIROLOGY","Score":null,"Total":0}
Torque Teno Virus Control by the Classical Pathway of Complement Activation—A Retrospective Analysis From a First-in-Human Trial Utilizing Sutimlimab
Torque Teno virus (TTV) load is linked with the functionality of its host's immune system and has been proposed as a potential monitoring tool for immune-modulating therapy. However, the immunological mechanisms of TTV control are incompletely understood. To assess the effect of the classical complement pathway on TTV, 64 healthy volunteers and 10 kidney transplant recipients treated with the anti-C1s antibody sutimlimab were analyzed for serum TTV copy numbers (c/mL) by qPCR. Overall, a correlation was observed between the decrease in complement activity caused by sutimlimab and the TTV load increase (ρ = −0.367, p < 0.001). Subgroup analysis indicated a trend toward TTV load increase in healthy volunteers following the highest sutimlimab dose compared to baseline (100 mg/kg body weight; median 3.5 log10 c/mL, interquartile range [IQR] 2.8–4.4 vs. 2.9 log10 c/mL, 0.8–3.5; p = 0.063). Administering multiple lower doses (30 mg/kg) also showed a trend toward TTV load increase in healthy volunteers (1.8 log10 c/mL, 0–2.3 vs. 1.9, 1.3–2.8; p = 0.054) and a significant increase in transplant recipients (3.5 log10 c/mL, 3.0–6.1 vs. 4.1, 3.5–6.4; p = 0.004). This report suggests a role for the classical complement pathway in controlling TTV load.
期刊介绍:
The Journal of Medical Virology focuses on publishing original scientific papers on both basic and applied research related to viruses that affect humans. The journal publishes reports covering a wide range of topics, including the characterization, diagnosis, epidemiology, immunology, and pathogenesis of human virus infections. It also includes studies on virus morphology, genetics, replication, and interactions with host cells.
The intended readership of the journal includes virologists, microbiologists, immunologists, infectious disease specialists, diagnostic laboratory technologists, epidemiologists, hematologists, and cell biologists.
The Journal of Medical Virology is indexed and abstracted in various databases, including Abstracts in Anthropology (Sage), CABI, AgBiotech News & Information, National Agricultural Library, Biological Abstracts, Embase, Global Health, Web of Science, Veterinary Bulletin, and others.